Lucrin Depot 3,75 , Lucrin Depot Diluent 3,75 mg, 2 mL Lyophilised microspheres for injection, Sterile diluent for injection
PDF Leaflet Revision Date: 01 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of endometriosis, prostate cancer, breast cancer, and central precocious puberty.
Dosage (summary)
3.75 mg subcutaneously once a month for adults; individualized for children based on weight.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Concomitant use with QT prolonging drugs
- Bupropion
- SSRIs
Contraindications
- Hypersensitivity to leuprolide
- Undiagnosed abnormal vaginal bleeding
- Pregnancy
- Breastfeeding
Common side effects
- Weight gain
- Hot flushes
- Headache
- Nausea
- Injection site reactions
Counselling Points
- Use non-hormonal contraception
- Report any unusual symptoms
- Monitor for signs of cardiovascular disease
Serious warnings
- Risk of convulsions
- Decreased bone mineral density
- Potential exacerbation of symptoms during initial treatment
Important Disclaimer
The Lucrin Depot 3,75 , Lucrin Depot Diluent 3,75 mg, 2 mL Lyophilised microspheres for injection, Sterile diluent for injection professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
